Drawing for PRITYRA

USPTO serial 78209675

PRITYRA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
Examiner
BOULTON, KELLY F
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PRITYRA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael E. Mangelson, Esq.

MICHAEL E MANGELSON ESQ STOEL RIVES LLP201 S MAIN ST STE 1100SALT LAKE CITY, UT 84111UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment or prevention of gastrointestinal disorders, infectious diseases, diseases involving varying levels of calcium in cells and outside cells, neurological or other central nervous system disorders, endocrine disorders, or bone metabolism disorders; pharmaceutical preparations for use in analgesiaACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Nov 28, 2007MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 28, 2007ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 2, 2007EX5GSOU EXTENSION 5 GRANTED
Dec 15, 2006EXT5SOU EXTENSION 5 FILED
Dec 15, 2006MAILPAPER RECEIVED
Aug 20, 2006EX4GSOU EXTENSION 4 GRANTED
Jul 7, 2006MAILPAPER RECEIVED
Jul 5, 2006EXT4SOU EXTENSION 4 FILED
Jan 30, 2006EX3GSOU EXTENSION 3 GRANTED
Jan 3, 2006EXT3SOU EXTENSION 3 FILED
Jan 3, 2006MAILPAPER RECEIVED
Jul 5, 2005EX2GSOU EXTENSION 2 GRANTED
Jun 15, 2005EXT2SOU EXTENSION 2 FILED
Jun 15, 2005MAILPAPER RECEIVED
Jan 25, 2005EX1GSOU EXTENSION 1 GRANTED
Dec 29, 2004EXT1SOU EXTENSION 1 FILED
Dec 29, 2004MAILPAPER RECEIVED
Jul 6, 2004NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 13, 2004PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 24, 2004NPUBNOTICE OF PUBLICATION
Feb 18, 2004CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jan 26, 2004MAILPAPER RECEIVED
Jan 23, 2004CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 25, 2003CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 23, 2003DOCKASSIGNED TO EXAMINER

Frequently asked questions

Related guidance